Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models.

Sartori A, Corno C, De Cesare M, Scanziani E, Minoli L, Battistini L, Zanardi F, Perego P.

Cancers (Basel). 2019 Apr 13;11(4). pii: E531. doi: 10.3390/cancers11040531.

2.

KiSS1 in regulation of metastasis and response to antitumor drugs.

Corno C, Perego P.

Drug Resist Updat. 2019 Jan;42:12-21. doi: 10.1016/j.drup.2019.02.001. Epub 2019 Feb 11. Review.

PMID:
30776659
3.

Alterations of RNA Metabolism by Proteomic Analysis of Breast Cancer Cells Exposed to Marycin: A New Optically Active Porphyrin.

Taverna E, De Bortoli M, Maffioli E, Corno C, Ciusani E, Trivulzio S, Pinelli A, Tedeschi G, Perego P, Bongarzone I.

Curr Mol Pharmacol. 2019;12(2):147-159. doi: 10.2174/1874467212666190204102112.

PMID:
30714537
4.

Role of FoxO Proteins in Cellular Response to Antitumor Agents.

Beretta GL, Corno C, Zaffaroni N, Perego P.

Cancers (Basel). 2019 Jan 14;11(1). pii: E90. doi: 10.3390/cancers11010090. Review.

5.

Tau Mutations as a Novel Risk Factor for Cancer-Response.

Rossi G, Redaelli V, Perego P, Ferrari R, Giaccone G, Tagliavini F.

Cancer Res. 2018 Nov 15;78(22):6525. doi: 10.1158/0008-5472.CAN-18-2730. Epub 2018 Oct 29. No abstract available.

PMID:
30373808
6.

Tau Mutations Serve as a Novel Risk Factor for Cancer.

Rossi G, Redaelli V, Contiero P, Fabiano S, Tagliabue G, Perego P, Benussi L, Bruni AC, Filippini G, Farinotti M, Giaccone G, Buiatiotis S, Manzoni C, Ferrari R, Tagliavini F.

Cancer Res. 2018 Jul 1;78(13):3731-3739. doi: 10.1158/0008-5472.CAN-17-3175. Epub 2018 May 24.

7.

Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group.

Perego P, Hempel G, Linder S, Bradshaw TD, Larsen AK, Peters GJ, Phillips RM; EORTC PAMM Group.

Cancer Chemother Pharmacol. 2018 Mar;81(3):427-441. doi: 10.1007/s00280-017-3502-7. Epub 2017 Dec 28. Review.

PMID:
29285635
8.

Molecular basis for the DNA damage induction and anticancer activity of asymmetrically substituted anthrapyridazone PDZ-7.

Misiak M, Heldt M, Szeligowska M, Mazzini S, Scaglioni L, Grabe GJ, Serocki M, Lica J, Switalska M, Wietrzyk J, Beretta GL, Perego P, Zietkowski D, Baginski M, Borowski E, Skladanowski A.

Oncotarget. 2017 Oct 10;8(62):105137-105154. doi: 10.18632/oncotarget.21806. eCollection 2017 Dec 1.

9.

FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.

Corno C, Stucchi S, De Cesare M, Carenini N, Stamatakos S, Ciusani E, Minoli L, Scanziani E, Argueta C, Landesman Y, Zaffaroni N, Gatti L, Perego P.

Biochem Pharmacol. 2018 Jan;147:93-103. doi: 10.1016/j.bcp.2017.11.009. Epub 2017 Nov 16.

PMID:
29155058
10.

Editorial: Targeting Drug-resistant and Metastatic Tumors by Interference with Tumor and Microenvironment-related Alterations.

Perego P.

Curr Med Chem. 2017;24(26):2808. doi: 10.2174/092986732426170914124127. No abstract available.

PMID:
28911301
11.

Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells.

Corno C, Gatti L, Arrighetti N, Carenini N, Zaffaroni N, Lanzi C, Perego P.

Biochem Pharmacol. 2017 Jul 15;136:40-50. doi: 10.1016/j.bcp.2017.04.002. Epub 2017 Apr 9.

PMID:
28404378
12.

RECQL4 Modulates MDR1 Expression and Chemoresistance-Letter.

Perego P.

Cancer Res. 2016 Dec 15;76(24):7290. Epub 2016 Dec 6. No abstract available.

13.

Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.

Fiorentini C, Fragni M, Perego P, Vezzoli S, Bonini SA, Tortoreto M, Galli D, Claps M, Tiberio GA, Terzolo M, Missale C, Memo M, Procopio G, Zaffaroni N, Berruti A, Sigala S.

J Clin Endocrinol Metab. 2016 Dec;101(12):4594-4602. Epub 2016 Sep 14.

14.

PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells.

Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, Gandellini P, Zaffaroni N, Perego P, Gatti L.

Toxicol Appl Pharmacol. 2016 Nov 1;310:9-19. doi: 10.1016/j.taap.2016.08.005. Epub 2016 Aug 20.

PMID:
27554045
15.

Synthetic sulfoglycolipids targeting the serine-threonine protein kinase Akt.

Costa B, Dangate M, Vetro M, Donvito G, Gabrielli L, Amigoni L, Cassinelli G, Lanzi C, Ceriani M, De Gioia L, Filippi G, Cipolla L, Zaffaroni N, Perego P, Colombo D.

Bioorg Med Chem. 2016 Aug 15;24(16):3396-405. doi: 10.1016/j.bmc.2016.05.031. Epub 2016 May 18.

PMID:
27316541
16.

Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.

Corno C, Gatti L, Lanzi C, Zaffaroni N, Colombo D, Perego P.

Curr Med Chem. 2016;23(15):1496-512. Review.

PMID:
27048336
17.

Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness.

Beretta GL, De Cesare M, Albano L, Magnifico A, Carenini N, Corna E, Perego P, Gatti L.

Tumori. 2016 Mar-Apr;102(2):144-9. doi: 10.5301/tj.5000471. Epub 2016 Feb 19.

PMID:
26917410
18.

Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy.

Perego P, Robert J.

Cancer Chemother Pharmacol. 2016 Jan;77(1):5-18. doi: 10.1007/s00280-015-2901-x. Epub 2015 Nov 20. Review.

PMID:
26589793
19.

Preface: histone deacetylases as therapeutic targets.

Perego P.

Crit Rev Oncog. 2015;20(1-2):2 pages before page 1. No abstract available.

PMID:
26277797
20.

Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis.

Bertolini G, D'Amico L, Moro M, Landoni E, Perego P, Miceli R, Gatti L, Andriani F, Wong D, Caserini R, Tortoreto M, Milione M, Ferracini R, Mariani L, Pastorino U, Roato I, Sozzi G, Roz L.

Cancer Res. 2015 Sep 1;75(17):3636-49. doi: 10.1158/0008-5472.CAN-14-3781. Epub 2015 Jul 3.

Supplemental Content

Loading ...
Support Center